Companies: 10,795·Total market cap: $144.5T
LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTXNASDAQHealthcare
$1.74
$-0.07(-3.87%)
Market Cap$45771213
P/E Ratio
52W High$2
52W Low$0.85

LAVA Therapeutics N.V. (LVTX) Revenue

Annual & quarterly revenue history · segment & region breakdown

LVTX · revenue · updated Jun 10, 2026

Core revenue metrics

LAVA Therapeutics N.V. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
34 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · LAVA Therapeutics N.V. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
LVTX revenue by year · LVTX revenue history · LVTX annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income LAVA Therapeutics N.V. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

LAVA Therapeutics N.V. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from LAVA Therapeutics N.V.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

LVTX revenue · 4 questions

LVTX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

LVTX revenueLVTX annual revenuewhat is LVTX revenueLVTX TTM revenue

Source: FMP · LAVA Therapeutics N.V. SEC filings · GAAP · LAVA Therapeutics N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026